Clearmind Medici Stock Price, News & Analysis

Clearmind Medicine (NASDAQ: CMND) has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) for its ongoing Phase 1/2a clinical trial of CMND-100, a MEAI-based oral drug candidate for Alcohol Use Disorder (AUD).

The trial, which recently began dosing its first participant, will be conducted at several prestigious institutions including Yale School of Medicine, Johns Hopkins University, and Hadassah-University Medical Center. At TASMC, the study will be led by Dr. David Zeltser, Director of Emergency Medicine Department.

The multinational, multi-center study aims to evaluate CMND-100's safety, tolerability, and pharmacokinetic profile, while assessing its preliminary efficacy in reducing alcohol cravings and consumption in AUD patients. This development addresses a significant global health issue, as AUD accounts for 4.7% of worldwide deaths according to WHO.

Clearmind Medicine (Nasdaq: CMND) has achieved a significant milestone by dosing the first participant with CMND-100, its proprietary MEAI-based oral drug candidate, in a Phase I/IIa clinical trial for Alcohol Use Disorder (AUD). This marks the first human administration of the company's novel treatment in a clinical setting.

The multinational, multicenter trial is being conducted at prestigious institutions including Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah-University Medical Center. The study aims to evaluate the safety, tolerability, and pharmacokinetic profile of CMND-100, while also assessing its preliminary efficacy in reducing alcohol cravings and consumption.

This development follows the company's June 5, 2025 announcement of the first participant enrollment. The trial will include both single- and multiple-dose studies to establish safety and optimal dosing parameters.

Clearmind Medicine (Nasdaq: CMND) announced the expansion of its Phase I/IIa clinical trial for CMND-100, a MEAI-based oral drug candidate targeting Alcohol Use Disorder (AUD). The company has added Hadassah-University Medical Center in Jerusalem as a new trial site, joining prestigious institutions including Yale School of Medicine, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and IMCA.

The trial aims to evaluate safety, tolerability, and pharmacokinetics of CMND-100, while exploring its potential to reduce alcohol cravings. The expansion targets the global AUD market affecting over 280 million people, representing a multibillion-dollar opportunity given current limited treatment options.

Clearmind Medicine (NASDAQ: CMND) has announced the enrollment of its first patient in a Phase I/IIa clinical trial for CMND-100, their MEAI-based oral drug candidate for treating Alcohol Use Disorder (AUD). The trial, conducted at Yale School of Medicine's Department of Psychiatry and Johns Hopkins University, will evaluate the drug's safety, tolerability, and pharmacokinetic profile.

The study targets individuals aged 18-60 who either report heavy binge drinking or are diagnosed with AUD. The U.S. substance use disorder treatment market, valued at $35.1 billion in 2021, is projected to reach $60.2 billion by 2029. The company aims to address limitations in current AUD treatments, which have shown limited effectiveness and adverse side effects.

Clearmind Medicine (Nasdaq: CMND) has partnered with a leading government affairs consulting firm to advance psychedelic-based treatments in the healthcare sector. The collaboration aims to navigate regulatory landscapes and promote acceptance of psychedelic therapeutics among U.S. policymakers.

The company's lead candidate, CMND-100, is currently undergoing Phase I/IIa clinical trials for Alcohol Use Disorder (AUD) at Yale School of Medicine and Johns Hopkins University. The partnership focuses on educating policymakers about psychedelics' therapeutic potential, particularly for treating conditions like PTSD and mental health disorders, while supporting the development of science-based regulatory frameworks.

Clearmind Medicine (NASDAQ: CMND) has expanded its Phase I/IIa clinical trial for CMND-100, a MEAI-based oral drug candidate treating Alcohol Use Disorder (AUD), by adding Tel Aviv Sourasky Medical Center (TASMC) as a new clinical site. The trial, which enrolled its first patient on June 5, 2025, is evaluating the safety, tolerability, and pharmacokinetic profile of CMND-100, while also studying its potential to reduce alcohol cravings. TASMC joins prestigious institutions including Yale School of Medicine's Department of Psychiatry and Johns Hopkins University School of Medicine. The TASMC study will be led by Dr. David Zeltser, Director of the Emergency Medicine Department. This expansion strengthens Clearmind's clinical network in addressing AUD, a condition responsible for 2.6 million deaths annually.

Clearmind Medicine (NASDAQ: CMND) has engaged a leading government and political affairs consulting firm to advance its psychedelic-based treatments and navigate regulatory landscapes. The company, focused on developing novel psychedelic-derived therapeutics, aims to foster greater acceptance among U.S. policymakers and advocate for science-based regulatory frameworks. CEO Dr. Adi Zuloff-Shani emphasized the importance of proactive engagement with regulators to ensure safe access to psychedelic therapies. The consulting firm will help educate policymakers on psychedelics' therapeutic potential and support the development of balanced regulations. Clearmind's lead candidate, CMND-100, is currently in Phase I/IIa clinical trials for AUD at Yale School of Medicine and Johns Hopkins University.

Clearmind Medicine (NASDAQ: CMND) has announced the enrollment of its first patient in a Phase I/IIa clinical trial for CMND-100, a MEAI-based oral drug candidate for treating Alcohol Use Disorder (AUD). The trial, conducted at Yale School of Medicine's Department of Psychiatry and Johns Hopkins University School of Medicine, will evaluate safety, tolerability, and pharmacokinetics, with preliminary efficacy assessments for reducing alcohol cravings. The study targets individuals aged 18-60 who either report heavy binge drinking or are diagnosed with AUD. CEO Dr. Adi Zuloff-Shani highlighted the significant market opportunity, noting that the U.S. substance use disorder treatment market, valued at $35.1 billion in 2021, is projected to reach $60.2 billion by 2029. The company aims to address limitations in current AUD treatments, which have shown limited effectiveness and adverse side effects.

Clearmind Medicine Inc. (NASDAQ: CMND) announces a live webinar titled "Gazing Through the Crystal Ball" scheduled for May 21, 2025, at 12:00 PM ET. The event will feature prominent experts in psychedelic science discussing the evolving landscape of the industry amid changing FDA policies and political climates.

The distinguished panel includes Rick Doblin, Founder and President of MAPS, Robin Carhart-Harris, neuropharmacologist at UCSF, Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine leading the development of CMND-100 for Alcohol Use Disorder, and Mark Haden, VP Business Development at Clearmind. The discussion will be moderated by Shannon Smadella, a social entrepreneur and former MAPS Canada board member.